XML 20 R27.htm IDEA: XBRL DOCUMENT v3.20.1

Long-Term Investments (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of ownership percentages of investee

		Ownership percentage
		December 31,				December 31,				Accounting
Name of related party		2019				2018				treatments
Braingenesis Biotechnology Co., Ltd.			0.17	%			0.17	%		Cost Method
Genepharm Biotech Corporation			0.72	%			0.72	%		Cost Method
BioHopeKing Corporation			7.13	%			7.13	%		Cost Method
BioFirst Corporation			15.89	%			15.84	%		Equity Method
Rgene Corporation			31.61	%			31.62	%		Equity Method

Schedule of extent the investee relies

Name of related party		The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.		No specific business relationship
Genepharm Biotech Corporation		No specific business relationship
BioHopeKing Corporation		Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation		Loaned from the investee and provides research and development support service
Rgene Corporation		Collaborating with the Company to develop and commercialize drugs

Schedule of long-term investment

		December 31, 2019				December 31, 2018
Non-marketable Cost Method Investments, net
Braingenesis Biotechnology Co., Ltd.		$	7,367			$	7,213
Genepharm Biotech Corporation			22,493				22,021
BioHopeKing Corporation			1,998,310				1,956,429
Sub total			2,028,170				1,985,663
Equity Method Investments, net
BioFirst Corporation			1,336,449				1,502,506
Rgene Corporation			-				-
Total		$	3,364,619			$	3,488,169

Schedule of equity investments

		Year Ended December 31,
		2019				2018
Share of equity method investee losses		$	(210,086	)		$	(193,012	)
Impairments							-
Total losses on equity investments		$	(210,086	)		$	(193,012	)

BioFirst [Member]

Schedule of balance sheets

		December 31, 2019				December 31, 2018
Current Assets		$	1,350,701			$	7,551,898
Noncurrent Assets			7,450,032				1,608,460
Current Liabilities			2,060,460				1,648,206
Noncurrent Liabilities			78,888				-
Shareholders' Equity			6,661,385				7,512,152

Schedule of statements of operation

		Year Ended December 31,
		2019				2018
Net sales		$	43,975			$	44,694
Gross profit			(37,160	)			(35,639	)
Net loss			(972,303	)			(1,569,813	)
Share of losses from investments accounted for using the equity method			(210,086	)			(193,012	)

Rgene [Member]

Schedule of balance sheets

		December 31, 2019				December 31, 2018
Current Assets		$	82,254			$	98,168
Noncurrent Assets			62,768				14,779
Current Liabilities			312,950				261,685
Noncurrent Liabilities			-				-
Shareholders' Equity (Deficit)			(167,928	)			(148,738	)

Schedule of statements of operation

		Year Ended December 31,
		2019				2018
Net sales		$				$
Gross Profit
Net loss			(53,877	)			(120,065	)
Share of loss from investments accounted for using the equity method			-				-

X

- Definition

Schedule of extent the investee relies.

+ References

No definition available.

+ Details

Name:	abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock
Namespace Prefix:	abvcd_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	abvcd_ScheduleOfLongTermInvestmentTableTextBlock
Namespace Prefix:	abvcd_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks
Namespace Prefix:	abvcd_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10

+ Details

Name:	srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix:	srt_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10

+ Details

Name:	srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix:	srt_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstAustraliaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: